Calumet, Inc. /DE
No enriched coverage for $CLMT in the last 7 days.
No SEC Form 4 filings for $CLMT in the last 30 days.
Calumet Director Daniel Sajkowski sold 3,310 shares of the company's stock on April 1st for a total of $114,062.60, reducing his stake by 3.88%. This transaction comes as Calumet has shown strong Q4 earnings, beating analyst expectations, and has seen its stock price rally towards a 52-week high with increased analyst attention, despite facing some near-term operational risks from unplanned maintenance.
Calumet, Inc. (NASDAQ:CLMT) has seen its stock price jump 26% in the last month and 47% over the last year. Despite this growth, its price-to-sales (P/S) ratio of 0.5x is significantly lower than the industry average, suggesting investors may be overlooking its potential. While the company's revenue has declined in recent years, analysts forecast a 7.1% annual growth over the next three years, outpacing the industry's projected 5.1% growth, which makes its low P/S ratio peculiar.
Calumet Specialty Products (CLMT) plans to offer $350 million in senior unsecured notes due 2031 to refinance existing senior debt due 2026 and 2027, thereby extending debt maturities and continuing a de-leveraging strategy. This move aligns with the company's efforts to reduce costs, enhance production in its specialty products segment, upgrade facilities, and expand its Montana Renewables operations, including the MaxSAF 150 project for sustainable aviation fuel. Despite weak financial performance and high leverage, analyst sentiment is neutral, with some optimism from cost reductions and strategic progress.
